Navigation Links
Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
Date:7/31/2008

PALO ALTO, Calif., July 31 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that it will move its corporate headquarters from Palo Alto, Calif. to the Chicago, Ill., area.

"The relocation will help us continue growing, extend our opportunities for partnerships and conduct business in one of the most dynamic markets in the country," said Timothy P. Walbert, president and chief executive officer of Horizon. "Chicago has all the elements to become a major life-science hub, but it's still rivaled by its bi-coastal counterparts. We wanted to relocate here to be an integral part of the market growth as well as leverage the existing market opportunities to grow our business."

The company will begin operations in its new headquarters in early August at the Illinois Science and Technology Park in Skokie, Ill., which formerly housed the Searle and then subsequently Pharmacia and Pfizer research and development offices. Horizon has approximately 50 full-time employees and consultants.

Mr. Walbert, who was recently named president and chief executive officer of Horizon and has approximately 20 years of proven experience launching and commercializing blockbuster drugs in the pain and arthritis fields, is focusing the Company's efforts on meeting the needs of arthritis and pain sufferers, specifically with its investigational compound HZT-501, a novel proprietary formulation of ibuprofen combined with famotidine in a single pill currently in Phase 3 clinical trials. Because approximately 25 percent of NSAID users may develop stomach ulcers, HZT-501 may offer patients effective pain relief with the confidence of GI-protection. Horizon expects to have data from the HZT-501 Phase 3 trials in fourth quarter of this year.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. BioHorizons Announces Agreement to Purchase Implant Logic Systems
4. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):